Review of Late-Breaking Trials From CRT 2022.

Authors :: Bhogal S
Aladin AI
Wermers JP
Morrison N
Gray N
Waksman R
Source :: Cardiovascular revascularization medicine : including molecular interventions [Cardiovasc Revasc Med] 2022 Jul; Vol. 40S, pp. 3-7. Date of Electronic Publication: 2022 May 16.
Publication Year :: 2022
Abstract: Competing Interests: Declaration of competing interest Ron Waksman – Advisory Board: Abbott Vascular, Boston Scientific, Medtronic, Philips IGT, Pi-Cardia Ltd.; Consultant: Abbott Vascular, Biotronik, Boston Scientific, Cordis, Medtronic, Philips IGT, Pi-Cardia Ltd., Swiss Interventional Systems/SIS Medical AG, Transmural Systems Inc., Venous MedTech; Grant Support: AstraZeneca, Biotronik, Boston Scientific, Chiesi, Medtronic, Philips IGT; Speakers Bureau: AstraZeneca; Investor: MedAlliance, Transmural Systems Inc. All other authors – None.

Subjects :: Humans
Treatment Outcome
Coronary Artery Disease surgery
Percutaneous Coronary Intervention adverse effects
Transcatheter Aortic Valve Replacement

Language :: English
ISSN :: 1878-0938
Volume :: 40S
Database :: MEDLINE
Journal :: Cardiovascular revascularization medicine : including molecular interventions
Publication Type :: Academic Journal
Accession number :: 35667967
Full Text :: https://doi.org/10.1016/j.carrev.2022.05.017